Literature DB >> 30024574

TYPICAL POLYPOIDAL CHOROIDAL VASCULOPATHY AND POLYPOIDAL CHOROIDAL NEOVASCULARIZATION.

Jun Won Jang1, Jong Min Kim, Se Woong Kang, Sang Jin Kim, Kunho Bae, Kyung Tae Kim.   

Abstract

PURPOSE: To compare typical polypoidal choroidal vasculopathy (T-PCV) and polypoidal choroidal neovascularization (P-CNV), which can be defined as two subtypes of PCV, and to elucidate the significance of the classification.
METHODS: Seventy-seven patients diagnosed with PCV and followed up for more than 12 months were reviewed. The PCV cases were divided into a T-PCV group (n = 36) and a P-CNV group (n = 41) according to the presence of features of pachychoroid or age-related macular degeneration. Angiographic and tomographic characteristics and changes in vision during the follow-up period were compared between the two groups.
RESULTS: Logarithm of the minimum angle of resolution visual acuity of T-PCV and P-CNV was 0.27 ± 0.31 and 0.62 ± 0.47 at baseline (P < 0.001) and 0.28 ± 0.41 and 0.54 ± 0.52 at the final visit (P = 0.006), respectively. A marginally higher rate of complete response to anti-vascular endothelial growth factor treatment was noted in the T-PCV group (47.2%) compared with the P-CNV group (26.8%) (P = 0.05). At the final visit, subfoveal fibrosis was noted in 11.1% of the T-PCV group and 39.0% of the P-CNV group (P = 0.009).
CONCLUSION: The two subtypes of PCV, P-CNV and T-PCV, behave differently in terms of angiographic and tomographic manifestations and visual outcomes. Classifying PCVs would be helpful not only for pathogenic implications, but also for prognostic significance.

Entities:  

Year:  2019        PMID: 30024574     DOI: 10.1097/IAE.0000000000002259

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  4 in total

1.  Choroidal thickness profile and clinical outcomes in eyes with polypoidal choroidal vasculopathy.

Authors:  Young Ho Kim; Boram Lee; Edward Kang; Jaeryung Oh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-01-08       Impact factor: 3.117

2.  Comparison of visual outcomes between therapy choices and subtypes of polypoidal choroidal vasculopathy (PCV) in Taiwan: a real-world study.

Authors:  Ling Yeung; Chi-Chun Lai; San-Ni Chen; Cheng-Kuo Cheng; Chung-May Yang; Yi-Ting Hsieh; Arslan Tsai; Chang-Hao Yang
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

3.  Five-year real-world outcomes of anti-vascular endothelial growth factor monotherapy versus combination therapy for polypoidal choroidal vasculopathy in a Chinese population: a retrospective study.

Authors:  Jingyuan Yang; Mingzhen Yuan; Erqian Wang; Song Xia; Youxin Chen
Journal:  BMC Ophthalmol       Date:  2019-11-21       Impact factor: 2.209

4.  Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy.

Authors:  Jingyuan Yang; Mingzhen Yuan; Song Xia; Youxin Chen
Journal:  J Ophthalmol       Date:  2019-12-14       Impact factor: 1.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.